Compare ULY & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ULY | KALA |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 6.0M |
| IPO Year | N/A | 2017 |
| Metric | ULY | KALA |
|---|---|---|
| Price | $2.46 | $0.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $11.50 | ★ $31.50 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 03-11-2026 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $127,932,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.74 | $0.51 |
| 52 Week High | $17.99 | $20.60 |
| Indicator | ULY | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 41.95 |
| Support Level | $2.12 | $0.58 |
| Resistance Level | $2.75 | $0.71 |
| Average True Range (ATR) | 0.35 | 0.05 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 15.13 | 11.92 |
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.